Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price was up 7.6% on Thursday . The company traded as high as $24.45 and last traded at $24.20. Approximately 91,031 shares changed hands during trading, a decline of 64% from the average daily volume of 252,244 shares. The stock had previously closed at $22.50.
Analyst Ratings Changes
A number of research analysts have recently issued reports on ELVN shares. HC Wainwright reissued a "buy" rating and issued a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Robert W. Baird boosted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research note on Friday, November 15th. Finally, BTIG Research assumed coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Enliven Therapeutics has a consensus rating of "Buy" and an average target price of $38.25.
Get Our Latest Report on Enliven Therapeutics
Enliven Therapeutics Stock Up 6.2 %
The stock has a fifty day moving average of $25.09 and a two-hundred day moving average of $24.28. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.58 and a beta of 1.02.
Insider Transactions at Enliven Therapeutics
In other news, insider Joseph P. Lyssikatos sold 37,878 shares of the business's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $28.16, for a total transaction of $1,066,644.48. Following the sale, the insider now owns 1,016,035 shares of the company's stock, valued at $28,611,545.60. The trade was a 3.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 3,350 shares of the company's stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $22.15, for a total value of $74,202.50. The disclosure for this sale can be found here. Insiders have sold a total of 125,624 shares of company stock valued at $3,479,160 in the last ninety days. 29.20% of the stock is currently owned by company insiders.
Institutional Trading of Enliven Therapeutics
A number of institutional investors have recently bought and sold shares of the company. Lord Abbett & CO. LLC acquired a new position in shares of Enliven Therapeutics during the 3rd quarter worth $8,199,000. Franklin Resources Inc. purchased a new position in Enliven Therapeutics during the 3rd quarter valued at about $559,000. Barclays PLC raised its position in Enliven Therapeutics by 295.8% during the third quarter. Barclays PLC now owns 56,217 shares of the company's stock worth $1,435,000 after acquiring an additional 42,012 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Enliven Therapeutics by 9.9% in the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock valued at $19,164,000 after purchasing an additional 67,813 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Enliven Therapeutics by 107.0% in the third quarter. Wellington Management Group LLP now owns 70,170 shares of the company's stock valued at $1,792,000 after purchasing an additional 36,267 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
